{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,21]],"date-time":"2026-10-21T18:41:53Z","timestamp":1792608113786,"version":"4.5.0"},"reference-count":80,"publisher":"Springer Science and Business Media LLC","issue":"11","license":[{"start":{"date-parts":[[2026,10,21]],"date-time":"2026-10-21T00:00:00Z","timestamp":1792540800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2026,10,21]],"date-time":"2026-10-21T00:00:00Z","timestamp":1792540800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"funder":[{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["82560237\uff0c81960242"],"award-info":[{"award-number":["82560237\uff0c81960242"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100007471","name":"Applied Basic Research Foundation of Yunnan Province","doi-asserted-by":"publisher","award":["202301AS070045"],"award-info":[{"award-number":["202301AS070045"]}],"id":[{"id":"10.13039\/100007471","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Yunnan Province Clinical Research Center for Neurological Disease","award":["202102AA310061"],"award-info":[{"award-number":["202102AA310061"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Neurol"],"published-print":{"date-parts":[[2026,11]]},"DOI":"10.1007\/s00415-026-14224-y","type":"journal-article","created":{"date-parts":[[2026,10,21]],"date-time":"2026-10-21T16:12:46Z","timestamp":1792599166000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Real-world safety and efficacy of lecanemab in the treatment of Alzheimer\u2019s disease: a systematic review and meta-analysis"],"prefix":"10.1007","volume":"273","author":[{"given":"Yunfeng","family":"Wu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Liuhui","family":"Zhu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jianzhun","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jie","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kangfu","family":"Yin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5801-5211","authenticated-orcid":false,"given":"Xinglong","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,10,21]]},"reference":[{"key":"14224_CR1","doi-asserted-by":"publisher","DOI":"10.1016\/j.arr.2024.102481","volume":"101","author":"PT Kamatham","year":"2024","unstructured":"Kamatham PT, Shukla R, Khatri DK, Vora LK (2024) Pathogenesis, diagnostics, and therapeutics for Alzheimer\u2019s disease: Breaking the memory barrier. Ageing Res Rev 101:102481","journal-title":"Ageing Res Rev"},{"issue":"5","key":"14224_CR2","first-page":"2937","volume":"16","author":"S Wang","year":"2024","unstructured":"Wang S, Jiang Y, Yang A, Meng F, Zhang J (2024) The expanding burden of neurodegenerative diseases: an unmet medical and social need. Aging Dis 16(5):2937\u20132952","journal-title":"Aging Dis"},{"issue":"2","key":"14224_CR3","doi-asserted-by":"publisher","first-page":"323","DOI":"10.3233\/JAD-190426","volume":"70","author":"YH El-Hayek","year":"2019","unstructured":"El-Hayek YH, Wiley RE, Khoury CP et al (2019) Tip of the iceberg: assessing the global socioeconomic costs of Alzheimer\u2019s disease and related dementias and strategic implications for stakeholders. J Alzheimers Dis 70(2):323\u2013341","journal-title":"J Alzheimers Dis"},{"issue":"3","key":"14224_CR4","doi-asserted-by":"publisher","first-page":"a006395","DOI":"10.1101\/cshperspect.a006395","volume":"2","author":"PS Aisen","year":"2012","unstructured":"Aisen PS, Cummings J, Schneider LS (2012) Symptomatic and nonamyloid\/tau based pharmacologic treatment for Alzheimer disease. Cold Spring Harb Perspect Med 2(3):a006395","journal-title":"Cold Spring Harb Perspect Med"},{"issue":"5054","key":"14224_CR5","doi-asserted-by":"publisher","first-page":"184","DOI":"10.1126\/science.1566067","volume":"256","author":"JA Hardy","year":"1992","unstructured":"Hardy JA, Higgins GA (1992) Alzheimer\u2019s disease: the amyloid cascade hypothesis. Science 256(5054):184\u2013185","journal-title":"Science"},{"issue":"4","key":"14224_CR6","doi-asserted-by":"publisher","first-page":"535","DOI":"10.1016\/j.jalz.2018.02.018","volume":"14","author":"CR Jack Jr","year":"2018","unstructured":"Jack CR Jr, Bennett DA, Blennow K et al (2018) NIA-AA research framework: toward a biological definition of Alzheimer\u2019s disease. Alzheimers Dement 14(4):535\u2013562","journal-title":"Alzheimers Dement"},{"key":"14224_CR7","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.p73","volume":"380","author":"E Mahase","year":"2023","unstructured":"Mahase E (2023) Alzheimer\u2019s disease: FDA approves lecanemab amid cost and safety concerns. BMJ 380:p73","journal-title":"BMJ"},{"issue":"1","key":"14224_CR8","doi-asserted-by":"publisher","DOI":"10.1038\/s44386-026-00044-7","volume":"3","author":"H Cheng","year":"2026","unstructured":"Cheng H, Kang L, Xu Y, Tanzi RE, Zhang C, Wang C (2026) Innovation breakthrough in the Alzheimer\u2019s disease pharmaceutical industry. NPJ Drug Discov 3(1):9","journal-title":"NPJ Drug Discov"},{"key":"14224_CR9","doi-asserted-by":"publisher","DOI":"10.3389\/fnagi.2023.1169499","volume":"15","author":"Y Qiao","year":"2023","unstructured":"Qiao Y, Chi Y, Zhang Q, Ma Y (2023) Safety and efficacy of lecanemab for Alzheimer\u2019s disease: a systematic review and meta-analysis of randomized clinical trials. Front Aging Neurosci 15:1169499","journal-title":"Front Aging Neurosci"},{"issue":"8","key":"14224_CR10","doi-asserted-by":"publisher","first-page":"3583","DOI":"10.1007\/s10072-024-07477-w","volume":"45","author":"K Abdelazim","year":"2024","unstructured":"Abdelazim K, Allam AA, Afifi B, Abdulazeem H, Elbehiry AI (2024) The efficacy and safety of lecanemab 10 mg\/kg biweekly compared to a placebo in patients with Alzheimer\u2019s disease: a systematic review and meta-analysis of randomized controlled trials. Neurol Sci 45(8):3583\u20133597","journal-title":"Neurol Sci"},{"issue":"1","key":"14224_CR11","doi-asserted-by":"publisher","DOI":"10.1186\/s13195-022-01124-2","volume":"14","author":"E McDade","year":"2022","unstructured":"McDade E, Cummings JL, Dhadda S et al (2022) Lecanemab in patients with early Alzheimer\u2019s disease: detailed results on biomarker, cognitive, and clinical effects from the randomized and open-label extension of the phase 2 proof-of-concept study. Alzheimers Res Ther 14(1):191","journal-title":"Alzheimers Res Ther"},{"key":"14224_CR12","unstructured":"LEQEMBI (lecanemab-irmb) injection, for intravenous or subcutaneous use [prescribing information]. Eisai Inc., Nutley, NJ; revised January 2026. US Food and Drug Administration. https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2026\/761269s011lbl.pdf"},{"issue":"3","key":"14224_CR13","doi-asserted-by":"publisher","first-page":"327","DOI":"10.1007\/s10654-025-01220-1","volume":"40","author":"JJ Claus","year":"2025","unstructured":"Claus JJ, Vom Hofe I, van Ijlzinga Veenstra A et al (2025) Generalizability of trial criteria on amyloid-lowering therapy against Alzheimer\u2019s disease to individuals with mild cognitive impairment or early Alzheimer\u2019s disease in the general population. Eur J Epidemiol 40(3):327\u2013337","journal-title":"Eur J Epidemiol"},{"key":"14224_CR14","doi-asserted-by":"publisher","DOI":"10.1186\/s13195-026-01966-0","author":"F Bellelli","year":"2026","unstructured":"Bellelli F, Delrieu J, van Kan GA et al (2026) Are pre-frail and frail amyloid positive individuals eligible to Lecanemab? A cross-sectional analysis from the Cogfrail real-world cohort. Alzheimers Res Ther. https:\/\/doi.org\/10.1186\/s13195-026-01966-0","journal-title":"Alzheimers Res Ther"},{"issue":"3","key":"14224_CR15","doi-asserted-by":"publisher","DOI":"10.1016\/j.tjpad.2025.100473","volume":"13","author":"L Qi","year":"2026","unstructured":"Qi L, Zheng F, Tu M et al (2026) Safety profiles of lecanemab: a systematic review and meta-analysis of randomized controlled trials and real-world evidence. J Prev Alzheimers Dis 13(3):100473","journal-title":"J Prev Alzheimers Dis"},{"issue":"7","key":"14224_CR16","doi-asserted-by":"publisher","first-page":"655","DOI":"10.1001\/jamaneurol.2025.1232","volume":"82","author":"M Paczynski","year":"2025","unstructured":"Paczynski M, Hofmann A, Posey Z et al (2025) Lecanemab treatment in a specialty memory clinic. JAMA Neurol 82(7):655\u2013665","journal-title":"JAMA Neurol"},{"issue":"6","key":"14224_CR17","doi-asserted-by":"publisher","DOI":"10.1007\/s00415-025-13142-9","volume":"272","author":"M Rosenbloom","year":"2025","unstructured":"Rosenbloom M, Schnee A, Nimma S, Lutz H, Gzesh D, Weisman D (2025) Monoclonal antibody administration in an academic institution and private neurological practice: a tale of two clinics. J Neurol 272(6):394","journal-title":"J Neurol"},{"issue":"6","key":"14224_CR18","doi-asserted-by":"publisher","first-page":"1549","DOI":"10.14283\/jpad.2024.159","volume":"11","author":"L Shields","year":"2024","unstructured":"Shields L, Hust H, Cooley SD et al (2024) Initial Experience with Lecanemab and Lessons Learned in 71 Patients in a Regional Medical Center. J Prev Alzheimers Dis. 11(6):1549\u20131562","journal-title":"J Prev Alzheimers Dis."},{"issue":"1","key":"14224_CR19","doi-asserted-by":"publisher","DOI":"10.1186\/s13195-025-01763-1","volume":"17","author":"N Bregman","year":"2025","unstructured":"Bregman N, Nathan T, Shir D et al (2025) Lecanemab in clinical practice: real-world outcomes in early Alzheimer\u2019s disease. Alzheimers Res Ther 17(1):119","journal-title":"Alzheimers Res Ther"},{"issue":"6","key":"14224_CR20","doi-asserted-by":"publisher","first-page":"1973","DOI":"10.1093\/brain\/awaf427","volume":"149","author":"LL Li","year":"2026","unstructured":"Li LL, Wang RZ, Wang Z et al (2026) Safety and short-term outcomes of lecanemab for Alzheimer\u2019s disease in China: a multicentre study. Brain 149(6):1973\u20131985","journal-title":"Brain"},{"issue":"3","key":"14224_CR21","doi-asserted-by":"publisher","DOI":"10.1002\/alz.71231","volume":"22","author":"W Liao","year":"2026","unstructured":"Liao W, Yu Q, Chen B et al (2026) Effectiveness, safety, and biomarker dynamics of lecanemab in Chinese Alzheimer\u2019s disease population: a multicenter real-world study. Alzheimers Dement 22(3):e71231","journal-title":"Alzheimers Dement"},{"issue":"1","key":"14224_CR22","doi-asserted-by":"publisher","DOI":"10.1186\/s13195-025-01912-6","volume":"17","author":"M Noguchi-Shinohara","year":"2025","unstructured":"Noguchi-Shinohara M, Yoshinobu T, Ozaki T et al (2025) Higher phosphorylated tau levels predict cognitive decline and amyloid-related imaging abnormalities during lecanemab treatment: clinical practice data. Alzheimers Res Ther 17(1):251","journal-title":"Alzheimers Res Ther"},{"issue":"5","key":"14224_CR23","doi-asserted-by":"publisher","DOI":"10.1016\/j.tjpad.2026.100541","volume":"13","author":"A Iwata","year":"2026","unstructured":"Iwata A, Sakata Y, Koizumi K et al (2026) Interim analysis of all-case post-marketing surveillance study in Japan: lecanemab in patients with early Alzheimer\u2019s disease. J Prev Alzheimers Dis 13(5):100541","journal-title":"J Prev Alzheimers Dis"},{"issue":"3","key":"14224_CR24","doi-asserted-by":"publisher","DOI":"10.1016\/j.tjpad.2026.100489","volume":"13","author":"L Shields","year":"2026","unstructured":"Shields L, Hust HS, Cooper GE et al (2026) Lecanemab over a two-year duration: key insights from a regional specialty medical center. J Prev Alzheimers Dis 13(3):100489","journal-title":"J Prev Alzheimers Dis"},{"key":"14224_CR25","doi-asserted-by":"crossref","unstructured":"Rezaii N, Dickson JR, Ford JN et al (2026) Real-World Characterization of Amyloid-Related Imaging Abnormalities (ARIA) in Lecanemab Treatment at an Academic Health System. medRxiv","DOI":"10.64898\/2026.01.23.26344739"},{"issue":"22","key":"14224_CR26","doi-asserted-by":"publisher","first-page":"2907","DOI":"10.1097\/CM9.0000000000003888","volume":"138","author":"W Kang","year":"2025","unstructured":"Kang W, Gao C, Li X et al (2025) Safety and effectiveness of lecanemab in Chinese patients with early Alzheimer\u2019s disease: evidence from a multidimensional real-world study. Chin Med J (Engl) 138(22):2907\u20132916","journal-title":"Chin Med J (Engl)"},{"key":"14224_CR27","volume":"372","author":"MJ Page","year":"2020","unstructured":"Page MJ, McKenzie JE, Bossuyt PM et al (2020) The PRISMA 2020 statement: an updated guideline for reporting systematic reviews. BMJ 372:n71","journal-title":"BMJ"},{"issue":"3","key":"14224_CR28","doi-asserted-by":"publisher","first-page":"270","DOI":"10.1016\/j.jalz.2011.03.008","volume":"7","author":"MS Albert","year":"2011","unstructured":"Albert MS, DeKosky ST, Dickson D et al (2011) The diagnosis of mild cognitive impairment due to Alzheimer\u2019s disease: recommendations from the National Institute on Aging-Alzheimer\u2019s Association workgroups on diagnostic guidelines for Alzheimer\u2019s disease. Alzheimers Dement 7(3):270\u2013279","journal-title":"Alzheimers Dement"},{"key":"14224_CR29","volume":"10","author":"M Cumpston","year":"2019","unstructured":"Cumpston M, Li T, Page MJ et al (2019) Updated guidance for trusted systematic reviews: a new edition of the Cochrane handbook for systematic reviews of interventions. Cochrane Database Syst Rev 10:ED000142","journal-title":"Cochrane Database Syst Rev"},{"issue":"10","key":"14224_CR30","first-page":"2127","volume":"18","author":"Z Munn","year":"2020","unstructured":"Munn Z, Barker TH, Moola S et al (2020) Methodological quality of case series studies: an introduction to the JBI critical appraisal tool. JBI Evid Synth. 18(10):2127\u20132133","journal-title":"JBI Evid Synth."},{"issue":"12","key":"14224_CR31","doi-asserted-by":"publisher","first-page":"2688","DOI":"10.1002\/aur.2619","volume":"14","author":"T May","year":"2021","unstructured":"May T, Pilkington PD, Younan R, Williams K (2021) Overlap of autism spectrum disorder and borderline personality disorder: a systematic review and meta-analysis. Autism Res 14(12):2688\u20132710","journal-title":"Autism Res"},{"issue":"4","key":"14224_CR32","doi-asserted-by":"publisher","first-page":"259","DOI":"10.1111\/jebm.12445","volume":"14","author":"SA Doi","year":"2021","unstructured":"Doi SA, Xu C (2021) The Freeman-Tukey double arcsine transformation for the meta-analysis of proportions: recent criticisms were seriously misleading. J Evid Based Med 14(4):259\u2013261","journal-title":"J Evid Based Med"},{"issue":"1","key":"14224_CR33","doi-asserted-by":"publisher","first-page":"55","DOI":"10.1002\/jrsm.1164","volume":"7","author":"AA Veroniki","year":"2016","unstructured":"Veroniki AA, Jackson D, Viechtbauer W et al (2016) Methods to estimate the between-study variance and its uncertainty in meta-analysis. Res Synth Methods 7(1):55\u201379","journal-title":"Res Synth Methods"},{"issue":"12","key":"14224_CR34","doi-asserted-by":"publisher","first-page":"1771","DOI":"10.1002\/sim.791","volume":"20","author":"J Hartung","year":"2001","unstructured":"Hartung J, Knapp G (2001) On tests of the overall treatment effect in meta-analysis with normally distributed responses. Stat Med 20(12):1771\u20131782","journal-title":"Stat Med"},{"issue":"10","key":"14224_CR35","doi-asserted-by":"publisher","DOI":"10.1002\/alz.70750","volume":"21","author":"S Chen","year":"2025","unstructured":"Chen S, Ou R, Wei Q et al (2025) Lecanemab treatment for Alzheimer\u2019s Disease of varying severities and associated plasma biomarkers monitoring: A multi-center real-world study in China. Alzheimers Dement 21(10):e70750","journal-title":"Alzheimers Dement"},{"issue":"3","key":"14224_CR36","doi-asserted-by":"publisher","first-page":"1346","DOI":"10.1177\/13872877251406619","volume":"109","author":"L Leng","year":"2026","unstructured":"Leng L, Liao Z, Lu P et al (2026) Real-world experience with baseline characteristics and safety of lecanemab for Alzheimer\u2019s disease in Eastern China. J Alzheimers Dis 109(3):1346\u20131356","journal-title":"J Alzheimers Dis"},{"issue":"1","key":"14224_CR37","doi-asserted-by":"publisher","DOI":"10.1186\/s13195-025-01943-z","volume":"18","author":"C Mao","year":"2026","unstructured":"Mao C, Wang W, Huang X et al (2026) Real world clinical practice of lecanemab at PUMCH dementia cohort: focus on dynamic imaging and biomarker evolution. Alzheimers Res Ther 18(1):32","journal-title":"Alzheimers Res Ther"},{"issue":"1","key":"14224_CR38","doi-asserted-by":"publisher","DOI":"10.1186\/s13195-025-01886-5","volume":"17","author":"J Shang","year":"2025","unstructured":"Shang J, Zhong S, Shang L et al (2025) Real-world application of lecanemab in early-stage Alzheimer\u2019s disease: a single-center prospective cohort analysis. Alzheimers Res Ther 17(1):249","journal-title":"Alzheimers Res Ther"},{"issue":"1","key":"14224_CR39","doi-asserted-by":"publisher","DOI":"10.1002\/alz.71044","volume":"22","author":"W Zhang","year":"2026","unstructured":"Zhang W, Liu H, Zhang C et al (2026) Six-month follow-up of ARIA-H and iron deposition in real-world lecanemab therapy for Alzheimer\u2019s disease: evidence from a Chinese 7T MRI cohort. Alzheimers Dement 22(1):e71044","journal-title":"Alzheimers Dement"},{"issue":"7","key":"14224_CR40","doi-asserted-by":"publisher","DOI":"10.1016\/j.tjpad.2026.100600","volume":"13","author":"Y Yan","year":"2026","unstructured":"Yan Y, Hu D, Kong L et al (2026) Reductions in neuropsychiatric symptoms after lecanemab treatment and their associations with imaging markers of \u03b2-amyloid clearance. J Prev Alzheimers Dis 13(7):100600","journal-title":"J Prev Alzheimers Dis"},{"issue":"8","key":"14224_CR41","doi-asserted-by":"publisher","DOI":"10.1002\/alz.71702","volume":"22","author":"H Wu","year":"2026","unstructured":"Wu H, Chen Q, Fang M et al (2026) Lecanemab use in Chinese patients with Alzheimer\u2019s disease: a 12-month multicenter real-world study. Alzheimers Dement 22(8):e71702","journal-title":"Alzheimers Dement"},{"issue":"6","key":"14224_CR42","doi-asserted-by":"publisher","DOI":"10.1002\/cns.70974","volume":"32","author":"Y Chang","year":"2026","unstructured":"Chang Y, Li H, Liu X et al (2026) Lecanemab reduces neuropsychiatric symptoms and related regional brain amyloid load in early Alzheimer\u2019s disease: a preliminary prospective study. CNS Neurosci Ther 32(6):e70974","journal-title":"CNS Neurosci Ther"},{"issue":"23","key":"14224_CR43","doi-asserted-by":"publisher","DOI":"10.3390\/jcm14238277","volume":"14","author":"AJ O\u2019Donnell","year":"2025","unstructured":"O\u2019Donnell AJ, Zhao X, Parr A, Aspinall S, Anderson TS (2025) Early Outcomes of Lecanemab for Alzheimer\u2019s Disease in the Veterans Health Administration. J Clin Med 14(23):8277","journal-title":"J Clin Med"},{"issue":"1","key":"14224_CR44","volume":"18","author":"BC Curd","year":"2026","unstructured":"Curd BC, Zubrick C, Brown C et al (2026) Real-world experience with lecanemab therapy for Alzheimer\u2019s disease in the Intermountain West. Alzheimers Dement Diagn Assess Dis Monit 18(1):e70251","journal-title":"Alzheimers Dement Diagn Assess Dis Monit"},{"issue":"2","key":"14224_CR45","volume":"18","author":"A Wallace","year":"2026","unstructured":"Wallace A, Zhou O, Hoang MN, Porter G, Padilla C, Marshall C (2026) Lecanemab and amyloid-related imaging abnormalities: real-world data from a single center experience. Alzheimers Dement Diagn Assess Dis Monit 18(2):e70377","journal-title":"Alzheimers Dement Diagn Assess Dis Monit"},{"key":"14224_CR46","doi-asserted-by":"crossref","unstructured":"Dowling T, Zhu S, Ford J et al (2026) Baseline Amyloid PET Centiloid Score and Risk of Amyloid-Related Imaging Abnormalities in Patients Treated With Lecanemab. AJNR Am J Neuroradiol","DOI":"10.3174\/ajnr.A9590"},{"issue":"3","key":"14224_CR47","doi-asserted-by":"publisher","DOI":"10.1002\/trc2.70291","volume":"12","author":"JR Brosch","year":"2026","unstructured":"Brosch JR, Wang S, Apostolova LG et al (2026) The Indiana University Brain Health Program to deliver amyloid-targeted therapy to Alzheimer\u2019s disease patients. Alzheimers Dement Transl Res Clin Interv 12(3):e70291","journal-title":"Alzheimers Dement Transl Res Clin Interv"},{"key":"14224_CR48","doi-asserted-by":"publisher","DOI":"10.1007\/s11239-026-03383-4","author":"BC Curd","year":"2026","unstructured":"Curd BC, Tolley ND, Santo M et al (2026) Prospective evaluation of systemic coagulation function during anti-amyloid monoclonal antibody therapy in Alzheimer\u2019s disease. J Thromb Thrombolysis. https:\/\/doi.org\/10.1007\/s11239-026-03383-4","journal-title":"J Thromb Thrombolysis"},{"issue":"3","key":"14224_CR49","volume":"18","author":"R Hakim","year":"2026","unstructured":"Hakim R, Harris K, Merrill L et al (2026) Real-world evidence for amyloid-targeted therapies: lecanemab and donanemab. Alzheimers Dement Diagn Assess Dis Monit 18(3):e70404","journal-title":"Alzheimers Dement Diagn Assess Dis Monit"},{"issue":"3","key":"14224_CR50","doi-asserted-by":"publisher","DOI":"10.1212\/WN9.0000000000000121","volume":"2","author":"AJ Liu","year":"2026","unstructured":"Liu AJ, Moghadam AA, Alam MS et al (2026) Clinical practice outcomes with lecanemab for Alzheimer disease. Neurology Open Access 2(3):e000121","journal-title":"Neurology Open Access"},{"key":"14224_CR51","doi-asserted-by":"publisher","DOI":"10.1016\/S1474-4422(26)00284-X","author":"R Mu","year":"2026","unstructured":"Mu R, Hofmann A, Gong K et al (2026) Dynamic changes in plasma biomarkers of Alzheimer\u2019s disease in patients treated with lecanemab: a longitudinal cohort study. Lancet Neurol. https:\/\/doi.org\/10.1016\/S1474-4422(26)00284-X","journal-title":"Lancet Neurol"},{"issue":"8","key":"14224_CR52","volume":"18","author":"S Rohatgi","year":"2026","unstructured":"Rohatgi S, Younan CM, Martinez Imbett RE et al (2026) Demographic and clinical characteristics of patients treated with lecanemab stratified by amyloid-related imaging abnormality status. Cureus 18(8):e114472","journal-title":"Cureus"},{"issue":"4","key":"14224_CR53","doi-asserted-by":"publisher","DOI":"10.1002\/alz.71392","volume":"22","author":"D Ryan","year":"2026","unstructured":"Ryan D, Lutz MW, Sides T, O\u2019Brien R, Johnson K (2026) Diffusion weighted imaging abnormalities and cerebral ischemia in a cohort of patients on lecanemab. Alzheimers Dement 22(4):e71392","journal-title":"Alzheimers Dement"},{"key":"14224_CR54","first-page":"1","volume":"10","author":"JM Alyanna Ferrer","year":"2026","unstructured":"Ferrer A, Moon J (2026) Lecanemab real-world treatment outcomes from cohort study in early Alzheimer\u2019s disease. Journal of Alzheimer\u2019s Disease Reports. 10:1\u20136","journal-title":"Journal of Alzheimer\u2019s Disease Reports."},{"key":"14224_CR55","doi-asserted-by":"publisher","DOI":"10.3389\/fnagi.2026.1801267","volume":"18","author":"T Iizuka","year":"2026","unstructured":"Iizuka T, Watanabe T, Kameyama M (2026) Aging modulates amyloid clearance kinetics during anti-amyloid therapy: evidence from real-world serial amyloid PET. Front Aging Neurosci 18:1801267","journal-title":"Front Aging Neurosci"},{"issue":"9","key":"14224_CR56","doi-asserted-by":"publisher","DOI":"10.1016\/j.tjpad.2026.100664","volume":"13","author":"M Noguchi-Shinohara","year":"2026","unstructured":"Noguchi-Shinohara M, Muramatsu D, Shima A et al (2026) Real-world long-term continuation of lecanemab therapy and the clinical utility of phosphorylated tau 181. J Prev Alzheimers Dis 13(9):100664","journal-title":"J Prev Alzheimers Dis"},{"issue":"3","key":"14224_CR57","doi-asserted-by":"publisher","DOI":"10.1002\/dad2.70492","volume":"18","author":"S Shimohama","year":"2026","unstructured":"Shimohama S, Bun S, Shikimoto R et al (2026) Real-world implementation of lecanemab in Alzheimer\u2019s disease: a Japanese cohort. Alzheimers Dement (Amst) 18(3):e70492","journal-title":"Alzheimers Dement (Amst)"},{"key":"14224_CR58","doi-asserted-by":"publisher","DOI":"10.1177\/13872877261488874","author":"R Takahashi","year":"2026","unstructured":"Takahashi R, Kashibayashi T, Fujita J et al (2026) Lower baseline cerebrospinal fluid amyloid-\u03b2 42 is associated with amyloid-related imaging abnormalities during real-world lecanemab treatment. J Alzheimers Dis. https:\/\/doi.org\/10.1177\/13872877261488874","journal-title":"J Alzheimers Dis"},{"issue":"6","key":"14224_CR59","doi-asserted-by":"publisher","DOI":"10.1016\/j.tjpad.2026.100562","volume":"13","author":"R Shimasaki","year":"2026","unstructured":"Shimasaki R, Kurihara M, Bannai T et al (2026) Amyloid-related imaging abnormalities in Japanese patients with Alzheimer\u2019s disease treated with Lecanemab: a real-world study. J Prev Alzheimers Dis 13(6):100562","journal-title":"J Prev Alzheimers Dis"},{"key":"14224_CR60","doi-asserted-by":"publisher","DOI":"10.1186\/s13195-026-02127-z","author":"N Bregman","year":"2026","unstructured":"Bregman N, de Barros NP, Nathan T et al (2026) Lecanemab in practice: AI-derived MRI predictors of benefit and amyloid related imaging abnormalities (ARIA). Alzheimers Res Ther. https:\/\/doi.org\/10.1186\/s13195-026-02127-z","journal-title":"Alzheimers Res Ther"},{"issue":"1","key":"14224_CR61","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1056\/NEJMoa2212948","volume":"388","author":"CH van Dyck","year":"2023","unstructured":"van Dyck CH, Swanson CJ, Aisen P et al (2023) Lecanemab in early Alzheimer\u2019s disease. N Engl J Med 388(1):9\u201321","journal-title":"N Engl J Med"},{"issue":"1","key":"14224_CR62","doi-asserted-by":"publisher","first-page":"19","DOI":"10.1016\/0303-8467(91)90004-9","volume":"93","author":"TH Ng","year":"1991","unstructured":"Ng TH, Leung SY, Wong MP (1991) Cerebral amyloid angiopathy in Chinese: incidence and significance. Clin Neurol Neurosurg 93(1):19\u201323","journal-title":"Clin Neurol Neurosurg"},{"key":"14224_CR63","doi-asserted-by":"publisher","DOI":"10.1016\/j.jns.2020.117037","volume":"416","author":"Y Yakushiji","year":"2020","unstructured":"Yakushiji Y, Tanaka J, Wilson D et al (2020) Proportion of intracerebral haemorrhage due to cerebral amyloid angiopathy in the East and West: comparison between single hospital centres in Japan and the United Kingdom. J Neurol Sci 416:117037","journal-title":"J Neurol Sci"},{"key":"14224_CR64","doi-asserted-by":"publisher","DOI":"10.3390\/ijms24010778","author":"M Pires","year":"2023","unstructured":"Pires M, Rego AC (2023) Apoe4 and Alzheimer\u2019s disease pathogenesis-mitochondrial deregulation and targeted therapeutic strategies. Int J Mol Sci. https:\/\/doi.org\/10.3390\/ijms24010778","journal-title":"Int J Mol Sci"},{"issue":"2","key":"14224_CR65","doi-asserted-by":"publisher","first-page":"496","DOI":"10.1016\/j.apsb.2021.10.002","volume":"12","author":"BR Troutwine","year":"2022","unstructured":"Troutwine BR, Hamid L, Lysaker CR, Strope TA, Wilkins HM (2022) Apolipoprotein E and Alzheimer\u2019s disease. Acta Pharm Sin B 12(2):496\u2013510","journal-title":"Acta Pharm Sin B"},{"issue":"8","key":"14224_CR66","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.0000000000213483","volume":"104","author":"SY Jeong","year":"2025","unstructured":"Jeong SY, Suh CH, Lim JS et al (2025) Incidence of amyloid-related imaging abnormalities in phase III clinical trials of anti-amyloid-\u03b2 immunotherapy: an updated meta-analysis. Neurology 104(8):e213483","journal-title":"Neurology"},{"key":"14224_CR67","unstructured":"European Medicines Agency. Leqembi recommended for treatment of early Alzheimer\u2019s disease: European Medicines Agency, November 14, 2024. Available from: https:\/\/www.ema.europa.eu\/en\/news\/leqembi-recommended-treatment-early-alzheimers-disease"},{"key":"14224_CR68","unstructured":"Eisai Co., Ltd.; Biogen Inc. Two-year real-world study of LEQEMBI\u00ae (lecanemab-irmb) in the United States [abstract]. Presented at: Alzheimer\u2019s Association International Conference (AAIC) 2025. 21: Toronto, Canada, July 30, 2025. Available from: https:\/\/www.eisai.com\/news\/2025\/news202552.html"},{"issue":"4","key":"14224_CR69","doi-asserted-by":"publisher","DOI":"10.1016\/j.tjpad.2025.100094","volume":"12","author":"N Villain","year":"2025","unstructured":"Villain N, Planche V, Lilamand M et al (2025) Lecanemab for early Alzheimer\u2019s disease: appropriate use recommendations from the French federation of memory clinics. J Prev Alzheimers Dis 12(4):100094","journal-title":"J Prev Alzheimers Dis"},{"issue":"1","key":"14224_CR70","doi-asserted-by":"publisher","first-page":"105","DOI":"10.1186\/s13195-024-01441-8","volume":"16","author":"LS Honig","year":"2024","unstructured":"Honig LS, Sabbagh MN, van Dyck CH et al (2024) Updated safety results from phase 3 lecanemab study in early Alzheimer\u2019s disease. Alzheimers Res Ther. 16(1):105","journal-title":"Alzheimers Res Ther."},{"key":"14224_CR71","doi-asserted-by":"publisher","DOI":"10.3389\/fnins.2024.1326784","volume":"18","author":"SJ Doran","year":"2024","unstructured":"Doran SJ, Sawyer RP (2024) Risk factors in developing amyloid related imaging abnormalities (ARIA) and clinical implications. Front Neurosci 18:1326784","journal-title":"Front Neurosci"},{"issue":"2","key":"14224_CR72","doi-asserted-by":"publisher","first-page":"357","DOI":"10.3233\/JAD-130296","volume":"37","author":"RL Handels","year":"2013","unstructured":"Handels RL, Xu W, Rizzuto D et al (2013) Natural progression model of cognition and physical functioning among people with mild cognitive impairment and Alzheimer\u2019s disease. J Alzheimers Dis 37(2):357\u2013365","journal-title":"J Alzheimers Dis"},{"issue":"2","key":"14224_CR73","doi-asserted-by":"publisher","first-page":"749","DOI":"10.3233\/JAD-201172","volume":"80","author":"A Llad\u00f3","year":"2021","unstructured":"Llad\u00f3 A, Froelich L, Khandker RK et al (2021) Assessing the progression of Alzheimer\u2019s disease in real-world settings in three European countries. J Alzheimers Dis 80(2):749\u2013759","journal-title":"J Alzheimers Dis"},{"issue":"2","key":"14224_CR74","doi-asserted-by":"publisher","first-page":"129","DOI":"10.31486\/toj.21.0084","volume":"22","author":"M Miyakawa-Liu","year":"2022","unstructured":"Miyakawa-Liu M, Feehan AK, Pai S, Garcia-Diaz J (2022) Rates of cognitive decline in 100 patients with Alzheimer disease. Ochsner J 22(2):129\u2013133","journal-title":"Ochsner J"},{"issue":"1 Suppl","key":"14224_CR75","first-page":"S39","volume":"9","author":"MM Williams","year":"2013","unstructured":"Williams MM, Storandt M, Roe CM, Morris JC (2013) Progression of Alzheimer\u2019s disease as measured by Clinical Dementia Rating Sum of Boxes scores. Alzheimers Dement 9(1 Suppl):S39-44","journal-title":"Alzheimers Dement"},{"issue":"12","key":"14224_CR76","doi-asserted-by":"publisher","DOI":"10.1002\/alz.70905","volume":"21","author":"CH van Dyck","year":"2025","unstructured":"van Dyck CH, Sperling R, Johnson K et al (2025) Long-term safety and efficacy of lecanemab in early Alzheimer\u2019s disease: results from the clarity AD open-label extension study. Alzheimers Dement 21(12):e70905","journal-title":"Alzheimers Dement"},{"key":"14224_CR77","volume":"4","author":"F Nonino","year":"2026","unstructured":"Nonino F, Minozzi S, Sambati L et al (2026) Amyloid-beta-targeting monoclonal antibodies for people with mild cognitive impairment or mild dementia due to Alzheimer\u2019s disease. Cochrane Database Syst Rev 4:CD016297","journal-title":"Cochrane Database Syst Rev"},{"key":"14224_CR78","unstructured":"BioArctic. New Leqembi-data presented at CTAD 2025 suggests potential to delay disease progression by up to 8.3 years with continued treatment, December 4, 2025. Available from: https:\/\/www.bioarctic.com\/en\/new-leqembi-data-presented-at-ctad-2025-suggests-potential-to-delay-disease-progression-by-up-to-8-3-years-with-continued-treatment\/"},{"issue":"5","key":"14224_CR79","doi-asserted-by":"publisher","first-page":"478","DOI":"10.1056\/NEJMc2215148","volume":"388","author":"NJ Reish","year":"2023","unstructured":"Reish NJ, Jamshidi P, Stamm B et al (2023) Multiple cerebral hemorrhages in a patient receiving lecanemab and treated with t-PA for stroke. N Engl J Med 388(5):478\u2013479","journal-title":"N Engl J Med"},{"key":"14224_CR80","doi-asserted-by":"publisher","DOI":"10.3390\/jcm14103420","author":"D Ryan","year":"2025","unstructured":"Ryan D, Feng W, Liu AJ (2025) Cerebrovascular management considerations in patients on AATs. J Clin Med. https:\/\/doi.org\/10.3390\/jcm14103420","journal-title":"J Clin Med"}],"container-title":["Journal of Neurology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00415-026-14224-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00415-026-14224-y","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00415-026-14224-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,10,21]],"date-time":"2026-10-21T18:02:01Z","timestamp":1792605721000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00415-026-14224-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,10,21]]},"references-count":80,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2026,11]]}},"alternative-id":["14224"],"URL":"https:\/\/doi.org\/10.1007\/s00415-026-14224-y","relation":{},"ISSN":["0340-5354","1432-1459"],"issn-type":[{"value":"0340-5354","type":"print"},{"value":"1432-1459","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,10,21]]},"assertion":[{"value":"24 July 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"10 October 2026","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"13 October 2026","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"21 October 2026","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"All authors have no actual or potential competing interests to declare.","order":1,"name":"Ethics","label":"Conflicts of interest","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":2,"name":"Ethics","label":"Ethical approval and consent to participate","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This study is a meta\u2011analysis of aggregated data from previously published trials and did not involve any new patient recruitment or data collection. All primary data are accessible from the cited original publications. The processed datasets and analysis code used in this meta\u2011analysis are available from the corresponding author upon reasonable request.","order":3,"name":"Ethics","label":"Data sharing statement","group":{"name":"EthicsHeading","label":"Declarations"}}],"article-number":"675"}}